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ABSTRACT: Background: The immune system is
a promising therapeutic target for disease modification
in Parkinson’s disease (PD), but appropriate immune-
related biomarkers must be identified to allow patient
stratification for trials and tracking of therapeutic
effects. The objective of this study was to investigate
whether immune markers in peripheral blood are candi-
date prognostic biomarkers through determining their
relationship with disease progression in PD.
Methods: Serum samples were collected in incident PD
cases and age-matched controls. Subjects were clinically
evaluated at baseline and 18 and 36 months. Ten cyto-
kines and C-reactive protein were measured, with data
reduction using principal-component analysis, and relation-
ships between component scores and motor (MDS Unified
Parkinson’s Disease Rating Scale — part 3) and cognitive
(Mini Mental State Examination [MMSE]) measures of dis-
ease severity/progression were investigated.
Results : TNF-a, IL1-b, IL-2, and IL-10 were higher in
PD (n 5 230) than in controls (n 5 93), P  0.001).
Principal-component analysis of log-transformed data
resulted in a 3-component solution explaining 51% of
the variance. Higher “proinflammatory” and lower “anti-
inflammatory” component scores were associated with
more rapid motor progression over 36 months
(P < 0.05), and higher “proinflammatory” component
scores were associated with lower MMSE at all times
(P < 0.05). Multiple linear regression analysis with
adjustment for covariates confirmed “anti-inflammatory”
component score was the strongest predictor of slower
motor progression (b 5 20.22, P 5 0.002), whereas
proinflammatory cytokines were associated with lower
baseline MMSE (b 5 20.175, P 5 0.007).
Conclusions: Serum immune marker profile is predic-
tive of disease progression in PD and hence a potential
prognostic biomarker. However, interventional trials are
needed to clarify whether peripheral immune changes
causally contribute to the progression of PD. VC 2016
The Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson and
Movement Disorder Society
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Parkinson’s disease (PD) is a common neurodegener-
ative disorder, affecting approximately 2%-3% of
people older than age 65. Although dopaminergic
treatments have symptomatic benefit for some of the
motor symptoms of the disease, their long-term use is
problematic, and there is an urgent need to develop
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therapies to slow the underlying disease process and
prevent progression to debilitating nondopaminergic
complications including postural instability and
dementia. Inflammation is a promising new therapeu-
tic target for disease modification.
Inflammatory change has been clearly demonstrated
in the PD brain, both at postmortem1-4 and using
[11C]-PK11195 positron emission tomography (PET)
imaging in vivo.5-7 Immune alterations have also been
reported to occur in the periphery, with altered cyto-
kine levels8 and monocyte9 and lymphocyte sub-
sets.10,11 Although often considered secondary to the
primary disease process, several lines of evidence sug-
gest that these observations reflect a direct pathogenic
role for the immune system in PD: (1) immune manipu-
lation in animal models of PD can alter disease suscep-
tibility and severity,4,12 (2) genetic studies in humans
show a significant association between major histocom-
patibility complex genes (HLA-DR) and PD risk,13,14
and (3) epidemiological studies show that individuals
who regularly take nonsteroidal anti-inflammatory
drugs have a reduced risk of developing PD.15
Although the literature to date has mainly focused on
disease risk, an arguably more relevant question is
whether the immune response influences the rate of dis-
ease progression following diagnosis, from a predomi-
nantly motor syndrome with Lewy body pathology
largely restricted to the brain stem to a condition with
marked gait and axial disturbance and ultimately
dementia with widespread cortical pathology.16 This
question is of particular importance because the most
realistic window for intervention with an immunomo-
dulatory disease-modifying therapy would be in the
early symptomatic phase. In addition, appropriate
immune-related biomarkers need to be identified to
facilitate future trials of immuno-modulatory therapies
to delay disease progression in PD.
Although central “markers” of immune activation
are available via PET neuroimaging, measurement of
immune markers in peripheral blood represents a
more accessible and practical method of studying and
monitoring the immune response in PD. There is
increasing evidence that peripheral immune changes
are highly relevant in neurodegenerative disease. For
example, in Alzheimer’s disease, systemic infections
and higher levels of serum TNF-a are associated with
faster rates of cognitive decline17 through a proposed
mechanism of immune-brain interaction leading to
activation of already “primed” microglia in the brain
and accelerated neurodegeneration.18 Furthermore cul-
tured peripheral blood mononuclear cells from PD
patients produce higher levels of inflammatory cyto-
kines in response to stimulation with lipopolysaccha-
rides compared with controls, and these cytokine
levels correlate with motor severity of disease.8 More
recently, an association between higher plasma
C-reactive protein (CRP) levels and more rapid motor
progression in PD has also been reported.19
This study investigated a panel of immune markers
in serum samples from a large incident PD cohort and
an age-matched control group, to ascertain whether
there was any association with disease status and
measures of disease severity and progression over a
subsequent 36 months of follow-up. Thus, for the first
time we explore the profile and relevance of serum
immune markers in newly diagnosed PD cases with
the aim of further informing our understanding of the
relationship between peripheral immune responses and
disease progression, and evaluating whether these eas-
ily accessible markers may constitute useful bio-
markers in PD.
Methods
Subjects
Subjects were participants in the Incidence of Cogni-
tive Impairment in Cohorts with Longitudinal Evalua-
tion in Parkinson’s Disease study (ICICLE-PD). The
cohort comprised 262 newly diagnosed PD patients
recruited between 2009 and 2011 from the community
and outpatient clinics in Newcastle and Cambridge,
United Kingdom, as well as unrelated control subjects
of similar age (n 5 99) recruited from the community.
Details of recruitment of 219 ICICLE-PD cases have
been previously published.20 An additional 43 cases
identified using the same recruitment methods who did
not complete the full ICICLE-PD neuropsychological/
imaging protocol within 6 months of referral required
for our previous study, but had sufficient clinical data
for the current study are included here. Idiopathic PD
was diagnosed according to United Kingdom Parkin-
son’s Disease Society Brain Bank criteria.21 Peripheral
blood samples were collected at enrollment. Subjects
were clinically and neuropsychologically assessed at
baseline and at 18- and 36-month follow-up visits. The
study was approved by the Newcastle and North Tyne-
side Research Ethics Committee. All patients provided
written informed consent.
Assessments
Baseline assessments included disease duration, fam-
ily history, medication history, and comorbid condi-
tions. Comorbidity was quantified in terms of number
of organ systems affected using the Cumulative Illness
Rating Scale (CIRS; range, 0-13).22 At each time, sub-
jects were assessed with a number of standardized
instruments including the Movement Disorder Society-
revised Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS),23 Mini Mental State Examination
(MMSE),24 and Geriatric Depression Scale-15 (GDS-
15).25 Levodopa-equivalent daily doses (LEDDs) were
calculated.26
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Measurement of Immune Markers
Venous blood samples were allowed to clot for 15
minutes prior to centrifugation at 2000 rpm for 15
minutes. Serum was removed and stored in 200-lL ali-
quots at -808C until assays were performed. A panel
of key inflammation-related markers was measured
using Meso Scale Discovery (Rockville) electrochemi-
luminescent immunoassays, including the V-PLEX
human proinflammatory panel 1 (IFN-g, IL-1b, IL-2,
IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-a),
and V-PLEX human CRP. Assays were run according
to the manufacturer’s instructions. Samples were proc-
essed in duplicate.
Statistical Analyses
Case-control comparisons of clinical/demographic
variables were performed using Student t tests for con-
tinuous variables and chi-square tests or Fisher’s exact
test for categorical variables. Mean immune marker
levels were compared using Mann-Whitney U tests.
Preliminary bivariate correlations between immune
marker levels and clinical measures were assessed
using Pearson’s correlation coefficients.
Principal-component analysis (PCA) was used to
reduce redundancy in the immune marker data set.
Resulting PCA component scores were extracted for
analysis of association with motor (UPDRS-III) and
cognitive (MMSE) measures of disease severity and
progression over time. Component scores were dicho-
tomized at the mean into high and low groups to
allow between-group comparisons of motor scores
(UPDRS III) and cognitive scores (MMSE) at the 3
assessment times using repeated-measures analysis of
variance (RMANOVA). Relationships between clinical
measures and immune component scores were further
evaluated using multiple linear regression analysis to
allow for the effects of covariates. Dependent variables
were UPDRS-III, MMSE, or rate of change in these
variables over time. In addition to immune component
scores (as continuous variables), other covariates con-
sidered for inclusion in the regression models included
age at study enrollment, age leaving full-time educa-
tion, sex, smoking status, comorbidity (CIRS systems
score), use of anti-inflammatory drugs, UPDRS III,
MMSE, GDS-15, and LEDD dose (all measured at
baseline). Selection of variables for inclusion in the
models was based on bivariate analyses (Pearson’s cor-
relations for continuous variables and Student t tests
for categorical variables), with variables showing asso-
ciation at P < 0.10 with the dependent clinical out-
come and PCA component scores selected for entry.
All statistical analyses were conducted using SPSS soft-
ware version 21.0
Results
Subjects
Of the 262 incident PD cases and 99 controls
included at baseline, 11 cases were excluded because
of a change in diagnosis at follow-up, and serum sam-
ples were unavailable for 21 cases and 6 controls;
thus, 230 cases and 93 controls were included.
Follow-up clinical and neuropsychological data were
available for 209 cases and 81 controls at 18 months
and 174 cases and 69 controls at 36 months. Demo-
graphic and clinical characteristics of subjects at base-
line are presented in Table 1. Case and control groups
were well matched, differing only in lower depression
scores in the control cohort, as would be anticipated.
Immune Marker Levels
Comparison of cytokine concentrations in PD cases
and controls revealed similar profiles in the 2 groups
(Fig. 1a). Mean levels of TNF-a, IL-1b, IL-2, and IL-10
were higher in PD versus controls (P  0.001, Mann-
Whitney U test, withstanding Bonferroni correction for
multiple testing; Supplementary Table 1). There were no
differences in CRP levels between cases and controls.
Prior to further analysis, immune marker and CRP data
were log-transformed using Ln(x 1 1) to overcome right
skewing of the data distributions without loss of zero
data. Bivariate correlation analyses provided preliminary
evidence of association between a number of immune
markers and clinical measures (Supplementary Table 2).
In the PD cohort, associations included IL-6 with higher
UPDRS-III motor scores (P < 0.05), TNF-a and CRP
TABLE 1. Demographic and clinical characteristics of sub-
jects at study enrollment
Variable
PD
(n 5 230)
Controls
(n 5 93) P
Age at study enrollment (years) 66.4 (9.5) 68.0 (8.0) 0.118
Disease duration at study
enrollment (years)
0.6 (0.5)
Sex (% male) 61.7 52.7 0.134
Age leaving full-time
education (years)
17.8 (3.7) 18.0 (3.4) 0.604
UPDRS-III 27.9 (11.5)
MMSE 28.8 (1.3) 29.0 (1.2) 0.078
GDS-15 2.9 (2.6) 1.0 (1.6) < 0.001
LEDD (mg) 194.5 (161.5)
CIRS systems score,
median, (range)
2 (0–7) 3 (0–7) 0.070
Anti-inflammatory
drug use (%)
32.6 33.3 0.900
Values shown are mean (SD) unless otherwise stated. Continuous variables
compared using Student t tests; categorical variables compared using chi-
square tests or Fisher’s exact test as appropriate. UPDRS-III, MDS Unified
Parkinson’s disease Rating Scale part 3; MMSE, Mini Mental State Exami-
nation; GDS-15, Geriatric Depression Scale–15 item; LEDD, levodopa-
equivalent daily dose; CIRS, Cumulative Illness Rating Scale (number of
organ systems affected).
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with faster rates of motor decline (change in UPDRS-III
per year), and IL-13 with slower rate of motor decline
(all P < 0.005); IFN-g, P < 0.005; TNF-a, P < 0.005;
IL-6, P < 0.05; and CRP, P < 0.05 with lower MMSE
scores and IL-1b and IL-2 with faster rate of cognitive
decline (change in MMSE per year; both, P < 0.005). In
the control group, there were bivariate correlations
between IL-1b, IL-6, and IL-8 and lower MMSE scores
and between IL-13 and slower rate of cognitive decline
(albeit at a significance level of P < 0.05 and notwith-
standing correction for multiple testing).
PCA
The immune marker data set (log-transformed) was
examined for suitability for PCA. Inspection of the
correlation matrix confirmed significant correlations
(r > 0.2) for each variable other than IL-8, and Bar-
tlett’s test of sphericity was statistically significant
(P < 0.001), indicating that the data were likely fac-
torizable. IL-1b and IL-8 were excluded, as Kaiser-
Meyer-Olkin (KMO) measures were below 0.5, indi-
cating sampling inadequacy. The overall KMO mea-
sure for the final analysis was 0.67.27 Three hundred
thirteen subjects were included (following removal
of outliers). PCA revealed 3 factors with Eigenvalues
> 1, explaining 23.5%, 16.1%, and 11.3% of the var-
iance. Inspection of the Scree plot also suggested 3
factors should be retained.28 The 3-component solu-
tion explained 51% of the variance. Oblique oblimin
rotation with Kaiser normalization was employed to
aid interpretation. Component loading and communal-
ities of the rotated solution are shown in Table 2.
Interpretation of the data necessitates an oversimplifi-
cation of the complex functions of these cytokines/
markers but, broadly speaking, indicates 2 compo-
nents that are mainly proinflammatory and one that is
mainly anti-inflammatory. Component 1 was desig-
nated “proinflammatory,” with the strongest loadings
from IFN-g and TNF-a, but also loadings from IL-2
and IL-10; component 2 was designated “anti-
inflammatory,” dependent on IL-4 and IL-13 as well
as IL-12p70; and component 3 was considered
“proinflammatory”, depending principally on CRP
and IL-6.
Association Between Component Scores
and Disease Measures
Comparison of mean immune component scores
indicated that component 1 scores (proinflammatory)
were significantly elevated in PD versus controls (P <
0.001; Student t test; Fig. 1c), but there were no sig-
nificant between-group differences for components
2 and 3 scores.
Component scores were dichotomized at the mean
into high- and low-score groups for comparison of
longitudinal UPDRS-III and MMSE scores within the
PD group (Fig. 2). High component 1 scores (proin-
flammatory) were associated with worsening of
UPDRS-III scores over time (RMANOVA, compo-
nent*time F 5 3.80, P 5 0.023). Component 2 scores
(anti-inflammatory) had an opposite effect, with
UPDRS-III remaining stable in those with high compo-
nent 2 scores versus worsening over time in those with
low scores (component*time F 5 5.34, P 5 0.005).
Although UPDRS-III scores at baseline appear to be
paradoxically higher (worse motor function) in the
group with high anti-inflammatory component 2
scores (Fig. 2b), this difference was not statistically
significant after correction for multiple testing and not
confirmed in linear correlation analyses. High compo-
nent 3 scores (pro-inflammatory) were associated with
FIG. 1. Comparison of immune marker profiles in cases (n 5 230) and
controls (n 5 93). Bars represent mean values; error bars show 95%
confidence intervals; *P < 0.001. (a) Cytokine levels (log scale); (b)
CRP levels; (c) PCA-derived component scores.
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TABLE 2. Rotated structure matrix for PCA of immune markers in 313 cases (post–outlier removal).
Inflammatory
Marker
Rotated Component Coefficients
Communalities
Component 1
Proinflammatory
Component 2
Anti-inflammatory
Component 3
Proinflammatory
IFN-g 0.673– 0.029 0.097 0.489
TNF-a 0.646 20.131 0.228 0.534
IL-10 0.591 0.012 0.076 0.372
IL-2 0.570 0.066 20.144 0.326
IL-4 20.191 0.702 0.273 0.547
IL-12p70 0.253 0.670 20.096 0.540
IL-13 0.020 0.664 20.133 0.471
IL-6 0.032 0.046 0.808 0.662
CRP 0.147 20.049 0.758 0.643
Rotation method: Oblimin rotation with Kaiser normalization.
Major loadings for each component are in italic.
FIG. 2. Longitudinal motor and cognitive parameters in the PD group (n 5 230), stratified by immune component scores. Mean UPDRS-III and
MMSE scores and 95% confidence intervals are shown. Components 1 and 3 were designated as “proinflammatory” and component 2 was desig-
nated as “anti-inflammatory.” (a-c) UPDRS–III at baseline, 18 months, and 36 months in those with high (greater than group mean) versus low (less
than group mean) component scores. (d-f) MMSE scores at each time in those with high (more than group mean) versus low (less than group mean)
component scores. (g) UPDRS-III and (h) MMSE scores in those with a high overall proinflammatory index (components 1 and 3 scores > group
mean, component 2 scores  group mean, n 5 32) versus a high overall anti-inflammatory index (component score 2 > group mean, component
scores 1 and 3 group  mean, n 5 26). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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higher UPDRS-III scores overall (main effect, F 5
8.46, P 5 0.004). Patients were further stratified into
those with a high overall proinflammatory index
(components 1 and 3 scores above group mean, com-
ponent 2 scores below group mean) versus a high
overall anti-inflammatory index (component score 2
above mean, component scores 1 and 3 below mean).
There was a clear separation of these 2 groups over
time in UPDRS-III scores with progressive worsening
in the high pro-inflammatory index group (group*time
F 5 10.31, P < 0.001; Fig. 2g) and a clinically signifi-
cant 13.3-point between-group difference at 36
months.
Analysis of MMSE scores in the PD group indicated
an overall reduction over all 3 assessment times in
those with high versus low component 1 scores
(RMANOVA F5 6.03, P 5 0.015), but there was no
time-dependent effect. No significant effects of compo-
nent 2 or 3 scores on MMSE were demonstrable.
Comparison of groups with a high overall proinflam-
matory index versus a high overall anti-inflammatory
index (as above) confirmed lower mean MMSE scores
in the proinflammatory group across all times (F 5
5.31, P 5 0.026; Fig 2h) but with a relatively modest
effect size (0.75-1.0 points). There was no significant
effect of component scores on MMSE scores in the
control group.
Associations between disease measures and immune
component scores were further evaluated using multi-
ple linear regression analyses to allow for correction
for potential confounding variables. Based on the rela-
tionships identified in the RMANOVAs, which indi-
cated that immune marker scores had an impact on
change in UPDRS-III over time, but an impact on
MMSE that was not time dependent, 2 regression
models were constructed, with change in UPDRS per
year and MMSE (baseline) as dependent variables.
Predictor variables included the 3 immune component
scores, and potential covariates were selected for
inclusion based on bivariate analyses (P < 0.10), as
described in the Methods section. For motor progres-
sion (change in UPDRS III/year), variables included
were immune component scores, age at study enroll-
ment, comorbidity (CIRS system score), and use of
anti-inflammatory drugs. The resulting model signifi-
cantly predicted motor progression (F6,196 5 4.64,
P < 0.001) with anti-inflammatory component 2 and
proinflammatory component 3 having opposing effects
in the model (b 5 -0.220, P 5 0.002, and b 5 0.121,
P 5 0.085, respectively), but there was no significant
effect of proinflammatory component 1, and there
were no significant covariate effects (P > 0.10; Supple-
mentary Table 3). For MMSE, variables entered
included immune component scores, age at study
enrollment, age leaving full-time education, and
comorbidity (CIRS system score). The resulting model
significantly predicted MMSE (F6,216 5 5.61,
P < 0.001) with component 1 (b 5 20.175, P 5
0.007), age (b 5 20.171, P 5 0.012), and age leaving
education (b 5 0.198, P 5 0.003) being significant
contributors to the model, but the contributions of
components 2 and 3 were nonsignificant (P > 0.10;
Supplementary Table 4). For both models, assump-
tions of linearity, independence of errors, homoscedas-
ticity, unusual points, and normality of residuals were
met.
Discussion
This is the first study to investigate serum immune
markers in a large cohort of newly diagnosed PD
patients, and demonstrates that the immune marker
profile in early disease is associated with cognitive
impairment and is predictive of the future rate of
motor progression. A more proinflammatory profile is
associated with lower MMSE scores and faster motor
decline, whereas a more anti-inflammatory profile is
associated with better cognitive ability and stable
motor function. The effect size of these immune fac-
tors is clinically significant, with a 13.3-point differ-
ence in UPDRS-III points between those with an
overall proinflammatory versus an overall anti-
inflammatory profile (Fig. 2g), more than double the
reported minimal clinically important change in the
UPDRS-III of 5 points.29 Our data are in keeping with
the hypothesis that peripheral immune changes might
influence disease progression in PD, although only
interventional trials using immunomodulatory thera-
pies will truly be able to demonstrate a causal link.
Nonetheless, this study highlights the potential of
serum immune markers as possible biomarkers in PD,
which may help facilitate such trials.
Existing data on serum or plasma cytokines in PD is
limited to a few reports of elevated cytokines (includ-
ing TNF-a, IL-6, IL-1, and IL-2) in small cohorts of
PD patients (n < 80) compared with controls30-33 and
2 small cross-sectional studies reporting association
between IL-6 and motor function34 and TNF-a and
the soluble IL-2 receptor and nonmotor severity,35
respectively. However, it is not clear whether any such
associations simply reflect a secondary effect of a
more advanced disease state on the immune system.
Longitudinal studies are necessary to investigate
whether inflammatory marker changes predate a more
aggressive disease course. Only 1 previous study, to
our knowledge, has adopted such a longitudinal
approach, investigating the role of CRP in 375 PD
cases and reporting an association with more rapid
motor deterioration (UPDRS-III),19 which is in keep-
ing with our findings.
Although studies to date have generally adopted a
highly selective approach in the immune markers
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measured, this study has taken a more unbiased data-
driven approach through measuring a panel of 11
markers with both pro- and anti-inflammatory effects
and using PCA to identify patterns associated with dis-
ease state and severity. The interpretation of the com-
ponents identified through PCA is not straightforward,
given the complexity of multiple functions attributed
to different cytokines,36 but nonetheless clear patterns
emerged from our data. Component 1 was mainly
driven by IFN-g and TNF-a, key proinflammatory
cytokines that mediate a Th1-type cell-mediated
immune response. IL-2 and IL-10 also contributed to
component 1. IL-2 has an accepted proinflammatory
role in the cell-mediated immune response. Although
IL-10 is generally considered to have predominantly
anti-inflammatory effects, its bioactivity is highly com-
plex, with roles in costimulation of B cells, NK cells,
and certain types of CD-8 T cells and production of
IFN-g.37 Component 2 had significant loadings from
IL-4 and IL-13, which have similar anti-inflammatory
effects on macrophages, suppressing IFN-g produc-
tion, and play an important role in the Th2-type
humoral immune response. However, IL-12p70 also
loaded onto this component despite its generally
accepted proinflammatory role.36 Component 3 was
dependent on IL-6 and CRP, 2 key proinflammatory
markers that are closely interrelated, with IL-6, being
an important inducer of hepatic synthesis of CRP.
Their segregation from proinflammatory/Th1 compo-
nent 1 was in keeping with the known role of IL-6 in
skewing the immune response from Th1 toward Th2
via inhibition of IFN-g production.38
Our data suggest that these 3 components of the
peripheral inflammatory/immune response can be seg-
regated not only in terms of their constituent markers,
but also in terms of their association with PD. Com-
ponent 1 was associated with the disease state itself,
being higher in patients than in controls and associ-
ated with lower baseline MMSE scores in the PD
group, suggesting that it may simply be a secondary
response to the degree of neurodegenerative pathol-
ogy. Conversely, component scores 2 and 3 were not
associated with disease status or MMSE but had prog-
nostic value in terms of motor progression independ-
ent of any covariate effects; the effects were in
opposing directions, as might be anticipated, with
component 2 associated with slower motor progres-
sion and component 3 with more rapid motor progres-
sion. Thus, some of the immune marker variation in
different individuals with PD might reflect intrinsic
differences in the proinflammatory/anti-inflammatory
balance of the peripheral immune response, independ-
ent of baseline disease state. However, it is also possi-
ble that lack of association with baseline clinical state
is because of a time lag between clinical measures of
the disease and underlying pathological change. The
underlying stimulant(s) of the peripheral immune
response in PD remain unclear, but abnormal a-
synuclein aggregates in the periphery may be
involved.39 Systemic infections might also be relevant
(particularly in the case of component 3: IL-6/CRP).
Although comorbidity was not a significant confound-
ing factor in our analyses, comorbidity scores do not
reflect minor infections around the time of sampling,
which this study did not capture.
Strengths of this study include the large unselected
cohort of PD cases recruited close to diagnosis, a well-
matched control cohort, measurement of a compre-
hensive panel of pro- and anti-inflammatory markers
with a data-driven approach to identify relevant varia-
tion, and the availability of longitudinal follow-up
data to 36 months to allow identification of prognos-
tic immune factors. Limitations include loss of varia-
tion in the immune marker data set, which is inherent
to the PCA process, and attrition in the cohort over
time because of death/loss to follow-up/withdrawal,
which is inevitable in longitudinal studies. Attrition
rates were 24% in the PD group and 26% in the con-
trol group over 36 months of follow-up, although
between-group comparisons of those assessed and not
assessed at 36 months did not reveal any significant
differences in terms of age, sex, disease duration, age
leaving education, baseline UPDRS-III, MMSE, GDS,
LEDD, comorbidity score, anti-inflammatory drug use,
or immune component score (Supplementary Table 5),
suggesting that any attrition bias is likely to have been
minimal. A further limitation is that MMSE may not
be sufficiently sensitive to change over a 36-month
period to allow us to capture any effect of the inflam-
matory profile on cognitive decline over time. Further-
more, the MMSE has shortcomings in measuring
executive function, although it is recommended as a
global screening tool for diagnosing dementia in PD.40
Further follow-up of the cohort is ongoing and will
ultimately allow us to evaluate whether immune
markers have utility in predicting long-term disease
outcomes including dementia. It would also be of
interest in future studies to explore whether the rele-
vance of immune markers varies in different disease
subtypes, for example, in monogenic forms of the dis-
ease associated with mutations in genes relevant to
immune function such as LRRK2,41 or in individuals
carrying PD-associated polymorphisms in HLA-DR.13
In summary, we present the first comprehensive
evaluation of serum immune markers in newly diag-
nosed PD compared with controls and demonstrate
contrasting associations between proinflammatory and
anti-inflammatory markers and subsequent disease
course. Although not useful as diagnostic biomarkers,
given the overlap between cases and controls, serum
immune marker profiles warrant further investigation
as potential prognostic biomarkers for patient
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stratification. In particular, once further longitudinal
outcome data are available in this or similar cohorts,
the next step would be to adopt a data modeling
approach using pro- and anti-inflammatory composite
scores derived directly from measured immune marker
levels to create a predictive model that can be con-
verted into an algorithm for use in individual patients.
In addition to its potential value in prognostication,
this work is also of relevance to the debate on whether
the peripheral immune balance between pro- and anti-
inflammatory responses has an etiological impact on
disease progression in PD. Our data are supportive of
such a hypothesis but cannot demonstrate a causal
link, and interventional studies of immune-modulating
therapies are needed to address this question.
Acknowledgments: The authors thank all the research subjects
involved in this project. We also acknowledge the following collabora-
tors within the ICICLE-PD Study Group: Dr Kirstie Anderson, MBBS,
MRCP, PhD (Newcastle upon Tyne Hospitals NHS Foundation Trust);
Professor Carol Brayne MBBS, FRCP, MD (University of Cambridge);
Professor David J. Brooks, MD, DSc (Imperial College London & Aar-
hus University, Denmark), Professor Patrick F. Chinnery, FRCP, PhD
(University of Cambridge); Professor Gary A. Ford, MB BChir, FRCP,
FESC (Newcastle University); Professor John T.. O’Brien, FRCPsych,
DM (University of Cambridge); Professor Adrian Owen, PhD, BSc (Uni-
versity of Western Ontario); Professor Trevor W. Robbins, PhD (Univer-
sity of Cambridge); Professor James B. Rowe, FRCP, PhD (University of
Cambridge); Professor Stephen Sawcer, MB, ChB, PhD (University of
Cambridge); Professor Thomas W. von Zglinicki, PhD (Newcastle Uni-
versity); Professor Keith Wesnes, PhD (Northumbria University).
References
1. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia
are positive for HLA-DR in the substantia nigra of Parkinson’s and
Alzheimer’s disease brains. Neurology 1988;38(8):1285-1291.
2. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta,
interleukin-6, epidermal growth factor and transforming growth
factor-alpha are elevated in the brain from parkinsonian patients.
Neurosci Lett 1994;180(2):147-150.
3. Loeffler DA, Camp DM, Conant SB. Complement activation in the
Parkinson’s disease substantia nigra: an immunocytochemical
study. J Neuroinflammation 2006;3:29.
4. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD41
lymphocytes into the brain contributes to neurodegeneration in a
mouse model of Parkinson disease. J Clin Invest 2009;119(1):182-
192.
5. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of micro-
glial activation with [11C](R)-PK11195 PET in idiopathic Parkin-
son’s disease. Neurobiol Dis 2006;21(2):404-412.
6. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and
dopamine terminal loss in early Parkinson’s disease. Ann Neurol
2005;57(2):168-175.
7. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose
metabolism in Parkinson’s disease with and without dementia.
Neuropsychopharmacology 2013;38(6):938-949.
8. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in
Parkinson’s disease. Brain Behav Immun 2009;23(1):55-63.
9. Grozdanov V, Bliederhaeuser C, Ruf WP, et al. Inflammatory dys-
regulation of blood monocytes in Parkinson’s disease patients.
Acta Neuropathol 2014;128(5):651-663.
10. Saunders JA, Estes KA, Kosloski LM, et al. CD41 regulatory and
effector/memory T cell subsets profile motor dysfunction in Parkin-
son’s disease. J Neuroimmune Pharmacol 2012;7(4):927-938.
11. Stevens CH, Rowe D, Morel-Kopp MC, et al. Reduced T helper
and B lymphocytes in Parkinson’s disease. J Neuroimmunol 2012;
252(1–2):95-99.
12. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuro-
inflammation and alpha-synuclein dysfunction potentiate each
other, driving chronic progression of neurodegeneration in a mouse
model of Parkinson’s disease. Environ Health Perspect 2011;
119(6):807-814.
13. Saiki M, Baker A, Williams-Gray CH, et al. Association of the
human leucocyte antigen region with susceptibility to Parkinson’s
disease. J Neurol Neurosurg Psychiatry 2010;81(8):890-891.
14. International Parkinson Disease Genomics Consortium, Nalls MA,
Plagnol V, et al. Imputation of sequence variants for identification
of genetic risks for Parkinson’s disease: a meta-analysis of genome-
wide association studies. Lancet 2011;377(9766):641-649.
15. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen
and risk of Parkinson disease. Neurology 2012;76(10):863-869.
16. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN,
Braak E. Staging of brain pathology related to sporadic Parkin-
son’s disease. Neurobiol Aging 2003;24(2):197-211.
17. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation
and disease progression in Alzheimer disease. Neurology 2009;
73(10):768-774.
18. Perry VH, Holmes C. Microglial priming in neurodegenerative dis-
ease. Nat Rrev Neurol 2014;10(4):217-224.
19. Umemura A, Oeda T, Yamamoto K, et al. Baseline Plasma C-
Reactive Protein Concentrations and Motor Prognosis in Parkinson
Disease. PLoS One 2015;10(8):e0136722.
20. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cog-
nitive impairment in incident Parkinson disease: The ICICLE-PD
Study. Neurology 2014;82(4):308-316.
21. Gibb WR, Lees AJ. The relevance of the Lewy body to the patho-
genesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psy-
chiatry 1988;51:745-752.
22. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am
Geriatr Soc 1968;16(5):622-626.
23. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder
Society-sponsored revision of the Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS): scale presentation and clinimetric testing
results. Mov Disord 2008;23(15):2129-2170.
24. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A
practical method for grading the cognitive state of patients for the
clinician. J Psychiatr Res 1975;12(3):189-198.
25. Sheikh JA, Yesavage JA. Geriatric Depression Scale (GDS):recent
findings and development of a shorter version. In: Brink TL, ed.
Clinical Gerontology: A Guide to Assessment and Intervention.
New York: Howarth Press; 1986.
26. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Sys-
tematic review of levodopa dose equivalency reporting in Parkin-
son’s disease. Mov Disord 2010;25(15):2649-2653.
27. Kaiser HF. An index of factorial simplicity. Psychometrika 1974;
39:32-36.
28. Cattell RB. The scree test for the number of factors. Multivariate
Behav Res 1966;1:245-276.
29. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically
important change on the unified Parkinson’s disease rating scale.
Mov Disord 2006;21(8):1200-1207.
30. Dufek M, Hamanova M, Lokaj J, et al. Serum inflammatory bio-
markers in Parkinson’s disease. Parkinsonism Relat Disord 2009;
15(4):318-320.
31. Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski
M. Evaluation of interleukins, ACTH, cortisol and prolactin con-
centrations in the blood of patients with parkinson’s disease. Neu-
roimmunomodulation 1996;3(2–3):131-134.
32. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson
DW. Association of circulating TNF-alpha and IL-6 with ageing
and parkinsonism. Acta Neurol Scand 1999;100(1):34-41.
33. Dursun E, Gezen-Ak D, Hanagasi H, et al. The interleukin 1 alpha,
interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels
in patients with early or late onset Alzheimer’s disease, mild cognitive
impairment or Parkinson’s disease. J Neuroimmunol 2015;283:50-57.
34. Scalzo P, Kummer A, Cardoso F, Teixeira AL. Serum levels of
interleukin-6 are elevated in patients with Parkinson’s disease and cor-
relate with physical performance. Neurosci Lett 2010;468(1):56-58.
35. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson
O. Non-motor symptoms in patients with Parkinson’s disease -
correlations with inflammatory cytokines in serum. PLoS One
2012;7(10):e47387.
W I L L I A M S - G R A Y E T A L
8 Movement Disorders, Vol. 00, No. 00, 2016
36. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their
relationship to the symptoms and outcome of cancer. Nat Rev
Cancer 2008;8(11):887-899.
37. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old
cytokine. Immunol Rev 2008;226:205-218.
38. J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochim
Biophys Acta 2011;1813(5):878-888.
39. Allen Reish HE, Standaert DG. Role of alpha-synuclein in inducing
innate and adaptive immunity in Parkinson disease. J Parkinsons
Dis 2015;15(1):1-19.
40. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures
for Parkinson’s disease dementia: recommendations from the
movement disorder society task force. Mov Disord 2007;22(16):
2314-2324.
41. Greggio E, Civiero L, Bisaglia M, Bubacco L. Parkinson’s disease
and immune system: is the culprit LRRKing in the periphery?
J Neuroinflammation 2012;9(1):94.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
S E R U M I M M U N E M A R K E R S A N D P D P R O G R E S S I O N
Movement Disorders, Vol. 00, No. 00, 2016 9
